Photys Therapeutics
Cambridge
About Photys Therapeutics
Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein post-translational modifications, going beyond degradation to restore protein function, repair signaling, and amplify endogenous disease-fighting mechanisms. Photys was co-founded by the Broad Institute’s leading bifunctional chemist, Amit Choudhary, and the Longwood Fund, alongside a scientific advisory board comprised of distinguished scientists and drug developers – MIT’s Angela Koehler, Salk’s Tony Hunter, Berkeley’s Dan Nomura, MPM’s Wendy Young, and Dana Farber’s Eric Fischer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $75.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2022)
- Website: photys.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/photys-therapeutics-22180 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.